Amgen Plans Phase III Program for Next-Gen Obesity Drug Targeting Liver and Kidney Diseases

A broad indication for MariTide could help Amgen secure Medicare coverage for the treatment following FDA approval, CEO Robert Bradway said at Wednesday’s Morgan Stanley Global Healthcare Conference.